Some biochemical aspects of the potential benefit of associating MD780515 with tricyclic antidepressants.
In the rat, suitable oral doses of tricyclic antidepressants (amitriptyline 20 mg kg-1, imipramine, desipramine 2.5 mg kg-1) are able to antagonize the increase of cardiac levels of intravenous tyramine after a pharmacologically active dose (3.5 mg kg-1 orally) of a reversible and specific type A MAO inhibitor, MD780515 (3-[4-(3-cyanophenylmethoxy)phenyl]-5-(methoxymethyl)-2-oxazolidinone). MD780515, in oral doses up to 35 mg kg-1, does not alter the liver microsomal drug metabolizing enzymes in the rat. Therefore, when given with tricyclic antidepressants, it should not interfere with their metabolism.
D000661:Amphetamine / Q000378:metabolism; D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage*; D001711:Biotransformation; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004359:Drug Therapy, Combination; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage*; D009206:Myocardium / Q000378:metabolism; D010080:Oxazoles / Q000008:administration & dosage*; D023303:Oxazolidinones; D051381:Rats; D011919:Rats, Inbred Strains; D014439:Tyramine / Q000378:metabolism
D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors; D010080:Oxazoles; D023303:Oxazolidinones; D003577:Cytochrome P-450 Enzyme System; D000661:Amphetamine; C026234:cimoxatone; D014439:Tyramine